Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

Published:2012-05 Issue:7 Volume:48 Page:1023-1030
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Seidel Christoph,Busch Jonas,Weikert Steffen,Steffens Sandra,Fenner Martin,Ganser Arnold,Grünwald Viktor

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

4. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised double blind phase III trial;Escudier;Lancet,2007

5. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors;Motzer;Cancer,2010

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients;JU Open Plus;2024-04

2. Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition;Discover Oncology;2023-09-23

3. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study;ESMO Open;2023-08

4. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma;Radiation Oncology;2021-11-02

5. Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor;Current Urology;2021-09-24